Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2012
At a glance
- Drugs TCN 032 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- 12 Sep 2012 Results presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 15 May 2012 Positive top-line data from this trial have been reported in a Theraclone Sciences media release.
- 21 Sep 2011 Status changed from not yet recruiting to recruiting, according to a Theraclone Sciences media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History